JD.com Q3 Net Profit Reaches RMB 6.5 Billion, Up 23% YoY, 44% Growth on Non-GAAP Basis
nashnova research
JD.com posted Q3 net profit of RMB 6.5 billion, up 23% year-on-year, while non-GAAP profit surged 44%; revenue returned to growth, but the real test is whether new-business loss narrowing and overseas synergies can hold.
What do the headline numbers actually say?
Q3 net revenue hit RMB 309.6 billion, slightly above the consensus estimate of RMB 309.1 billion. Net profit attributable to shareholders reached RMB 6.5 billion, up 23% year-on-year.
On a non-GAAP basis, net profit rose 44% to RMB 8.3 billion, accelerating from the prior quarter. This means → strip out one-off and non-cash items, and JD's actual earnings power improved nearly twice as fast as the headline figure suggests.
Year-to-date revenue totalled RMB 971.7 billion, up just 1.56%. In plain terms = profit is running far ahead of revenue — JD is earning more by spending less, not by selling more.
What is driving the profit acceleration?
CEO Xu Ran flagged two lines: retail resilience + new-business loss narrowing. User base expanded while marketing expenses fell meaningfully year-on-year — more users acquired for less money.
The retail segment acted as an "anchor" — operating margin held roughly stable against a high base. This means → retail delivered no upside surprise but no drag either; the profit acceleration came mainly from new businesses bleeding less.
New businesses narrowed losses both year-on-year and quarter-on-quarter, led by JD Takeaway and Jingxi. CFO Shan Su pledged to "keep improving efficiency and maintain financial discipline."
Where does the overseas push stand?
The acquisition of European consumer-electronics retailer CECONOMY is complete. Xu Ran called it "an important step" in JD's global retail and logistics footprint.
Cross-border platform Joybuy is showing good momentum; the CFO expects further acceleration as CECONOMY synergies materialise.
This reflects a shift from "Chinese e-commerce company" to "global retail-plus-logistics company" — but the market is still waiting to see synergies show up in actual financial results.
How is subsidiary JD Health performing?
JD Health (06618) posted Q3 revenue of RMB 20 billion, maintaining double-digit growth; non-IFRS operating profit came in at RMB 1.57 billion.
AI doctor "Dawei" saw daily health-service interactions jump more than 5× year-on-year; the AI clinical workstation "Medwork" has launched specialist pilots with Peking University Cancer Hospital and other institutions. In plain terms = AI in JD's health arm has moved beyond concept stage into real hospital workflows.
Yet profitability is under pressure as AI healthcare and supply-chain expansion costs are still ramping. This means → when AI spending converts into profit is the single most important number to watch for JD Health going forward.
What is new on the supply-chain and fulfilment side?
Over 110 pharmaceutical companies have chosen JD Health for new-drug launches; Q3 alone saw more than 50 launches, with cumulative online launches exceeding 100 — surpassing the full-year 2025 total, per the company.
At the China International Import Expo, JD Health signed agreements with Pfizer, Merck, Takeda and over 20 other global pharma brands, extending cooperation from product launches to patient management and full-disease-cycle care.
On fulfilment, the "instant medicine delivery" overnight service now covers more than 300 cities nationwide; cold-chain delivery has been upgraded in multiple cities for temperature-controlled shipping of over 100 drug types. Offline, two JD Health general clinics opened in Beijing.
What will the market be watching next?
Can new-business loss narrowing continue? The pullback in losses at takeaway and Jingxi was the key driver of this quarter's profit acceleration; if the narrowing slows, profit growth will decelerate.
CECONOMY synergy timeline — completing the deal is step one; when revenue and cost synergies show up in the numbers will determine whether the overseas narrative holds.
JD Health AI monetisation pace — the surge in daily interactions proves demand exists, but the timetable for profit conversion remains uncertain. This reflects a company in transition: profit improvement has been delivered, but the next growth engines are still unproven.
市场有风险,内容仅供研究参考,不构成投资建议。
